Serum Interleukin-23/17 Levels in Ankylosing Spondylitis Patients Treated with Nonsteroidal Anti-Inflammatory Drugs: A Prospective Cohort Study

Basit Öğe Kaydı
dc.contributor.authorDeveci, Hulya
dc.contributor.authorTurk, Ayla Cagliyan
dc.contributor.authorOzmen, Zeliha Cansel
dc.contributor.authorDeveci, Koksal
dc.date.accessioned2021-11-01T15:01:57Z
dc.date.available2021-11-01T15:01:57Z
dc.date.issued2019
dc.department[Belirlenecek]
dc.description.abstractEtiopathogenesis of ankylosing spondylitis (AS), a major subtype of a group of chronic inflammatory diseases known as spondyloarthropathies, is not clearly understood yet. In this study, we aimed to investigate the interleukin 23 (IL-23)/interleukin-17 (IL-17) pathway, which is a new cytokine pathway in inflammatory diseases. We evaluated serum IL-17 and IL-23 levels after 1-year follow-up in AS patients using only nonsteroidal anti inflammatory drugs (at need or continue). Forty-four AS patients and 40 healthy controls were included in the study. Clinical evaluations of disease activity were performed. Serum tumor necrosis factor-alpha (TNF-alpha), IL-6, IL-17, and IL-23 levels were evaluated. IL-17 and IL-23 levels of the patient group at baseline and 12 months were lower than the control group. There was no significant difference between the baseline and 12th month evaluations of the patient group. TNF-alpha levels were similar in all groups (in the baseline and 12th month of the patient group and in the control group). Although our results are in contrast to the literature findings, the IL-23/IL-17 pathway is a newly discovered pathway, and there may still be unknowns. New studies involving larger patient groups are needed for the factors affecting serum IL-23/IL-17 levels in patients with AS. We also think that it will be useful to make more comprehensive and long-term studies about which patients will respond well to IL-23/IL-17 blockade.
dc.identifier.doi10.1089/jir.2019.0052
dc.identifier.endpage576en_US
dc.identifier.issn1079-9907
dc.identifier.issn1557-7465
dc.identifier.issue9en_US
dc.identifier.pmid31347941
dc.identifier.scopus2-s2.0-85071783765
dc.identifier.scopusqualityQ3
dc.identifier.startpage572en_US
dc.identifier.urihttps://doi.org/10.1089/jir.2019.0052
dc.identifier.urihttps://hdl.handle.net/11491/6779
dc.identifier.volume39en_US
dc.identifier.wosWOS:000485294800008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofJournal Of Interferon And Cytokine Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectankylosing spondylitisen_US
dc.subjectTNF-alphaen_US
dc.subjectIL-6en_US
dc.subjectIL-17en_US
dc.subjectIL-23en_US
dc.titleSerum Interleukin-23/17 Levels in Ankylosing Spondylitis Patients Treated with Nonsteroidal Anti-Inflammatory Drugs: A Prospective Cohort Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu